{"id":495070,"date":"2025-10-13T02:50:22","date_gmt":"2025-10-13T02:50:22","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/495070\/"},"modified":"2025-10-13T02:50:22","modified_gmt":"2025-10-13T02:50:22","slug":"integrase-inhibitors-maintain-efficacy-despite-outside-mutations-uk-study-finds","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/495070\/","title":{"rendered":"Integrase inhibitors maintain efficacy despite \u201coutside\u201d mutations, UK study finds"},"content":{"rendered":"

New data out of the United Kingdom offer some reassuring news regarding the clinical impact of non-integrase mutations on HIV treatment outcomes among recently diagnosed people starting integrase inhibitor-based therapy. They also help reinforce recommendations regarding the best ways for us to monitor for, and adjust to, the risk for antiretroviral drug resistance in a range of clinical settings.<\/p>\n

Highlighted Study Population and Methods<\/strong><\/p>\n

This study analyzed samples from 1,106 people in the United Kingdom who had recently acquired HIV-1. Recent infection (within six months) was defined using the\u00a0UK RITA algorithm<\/a>; RITA excludes those already on treatment at sampling.<\/p>\n

Whole-genome sequencing was performed on pre-treatment plasma samples obtained between 2015 and 2021, and these sequences were linked to clinical data. The analysis focused on non-integrase regions and mutations previously implicated in integrase strand transfer inhibitor (INSTI) resistance: Env (Y61H, A539V), Gag-NC (N8S), and 3\u2019 polypurine tract (3\u2019PPT c9053t).<\/p>\n

Of the participants, 375 (34%) started an INSTI-based\u00a0antiretroviral therapy\u00a0(ART); 337 (90%) were men, median age was33 years, and 196 (52%) had subtype B infection. Median number of viral load (VL) measurements in 24 months after ART start was four. Evaluated endpoints were time to viral suppression and occurrence of viral load blips.<\/p>\n

Key Findings<\/strong><\/p>\n